Table 3 Cox proportional hazards analysis of disease-free survival and overall survival for MA.12 GR methylation study patients

  A

0.869 [0.445–1.698]

0.807 [0.464–1.403]

  C

0.423 [0.181–0.986]

0.492 [0.261–0.927]

  D

0.867 [0.437–1.722]

1.155 [0.692–1.928]

  F

0.816 [0.457–1.457]

0.707 [0.438–1.140]

  L

1.403 [0.750–2.625]

1.470 [0.886–2.438]

  P

1.059 [0.518–2.164]

1.249 [0.725–2.155]

  U

1.742 [1.008–3.011]

1.282 [0.803–2.046]

  W

1.294 [0.716–2.339]

1.227 [0.755–1.997]

 Age

  ≤ 45 years

1

1

  > 45 years

1.577 [0.933–2.666]

1.340 [0.875–20.53]

 Stage (pathological)

  I

1

1

  II

1.536 [0.380–6.428]

1.724 [0.543–5.470]

  III

1.352 [0.247–7.381]

2.136 [0.566–8.055]

 Pathological T-stage

  T1

1

1

  T2

1.891 [1.059–3.377]

1.418 [0.903–2.228]

  T3/T4

1.310 [0.440–3.898]

1.552 [0.713–3.379]

 Nodal status

  Node negative

1

1

  1–3 nodes

1.071 [0.446–2.571]

1.679 [0.763–3.696]

  4–9 nodes

1.357 [0.515–3.572]

1.832 [0.769–4.362]

  10+ nodes

4.863 [1.565–15.109]

6.285 [2.106–18.754]

 Adjuvant chemotherapy

  CEF

1

1

  CMF

0.840 [0.446–1.583]

0.794 [0.473–1.332]

  AC

0.570 [0.274–1.186]

0.662 [0.373–1.174]

 Treatment

  Placebo

1

1

  Tamoxifen

1.029 [0.609–1.741]

0.860 [0.561–1.318]

  C

0.396 [0.164–0.957]

0.492 [0.252–0.957]

  U

1.786 [1.025–3.113]

1.318 [0.822–2.115]